Latest News

Tiziana Life Sciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company

22 May 2020

TLSA announces its' Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company

Read more

TR-1: Standard form for notification of major holdings

21 May 2020

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

...

Read more

Exercise of Warrants and Issue of Equity

18 May 2020

London, New York, 18 May 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease...

Read more

ASCO Abstract 298561: Phase 2a Safety and Efficacy of Milciclib, a Pan-Cyclin Dependent Kinase Inhibitor, in Unresectable, Sorafenib-Refractory or -Intolerant Hepatocellular Carcinoma Patients

14 May 2020

Title: 

Phase 2a Safety and Efficacy of Milciclib, a Pan-Cyclin Dependent Kinase Inhibitor, in Unresectable, Sorafenib-Refractory or -Intolerant Hepatocellular Carcinoma Patients.

Authors and Affiliations:

 Erica Villa, Fabio Piscaglia, Rabit Geva, George Dalecos, George Papatheodoridis, Marina Ciomei, Christina Davite, Patrizia Crivori, Vaseem Palejwala, Jules...

Read more

ASCO Abstract 307309: Safety and Clinical Activity of Combination Treatment with Regorafenib and Milciclib in Liver Transplant Patients with Hepatocellular Carcinoma Recurrence

14 May 2020

ASCO Abstract: 307309 Safety and Clinical Activity of Combination Treatment with Regorafenib and Milciclib in Liver Transplant Patients with Hepatocellular Carcinoma Recurrence

Read more

Tiziana Life Sciences Announces Online Publication of Two Abstracts at ASCO Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma

14 May 2020

Online Publication of Two Abstracts at ASCO Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma

Read more

Page 1 of 13 Next